Please ensure Javascript is enabled for purposes of website accessibility

ShockWave Medical's Revenue Soars in Its Public Debut

By Brian Feroldi – May 10, 2019 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The medical device maker's first earnings report as a public company featured explosive revenue growth and upbeat full-year guidance.

ShockWave Medical (SWAV 2.84%), a medical device company focused on treating cardiovascular disease, reported its first-quarter earnings on Wednesday.

This was ShockWave's first earnings report since hitting the public markets in March, so the pressure was on for the company to deliver. It posted impressive revenue growth of 450% during the quarter, albeit off of a small base. Management stated that product adoption was strong both in the U.S. and in international markets.

Expenses are ramping quickly as it works to build out its commercial team and expand its pipeline, but that's to be expected since the company is currently in hypergrowth mode. 

ShockWave Medical's first quarter: The raw numbers


Q1 2019

Q1 2018

Year-Over-Year  Growth


$7.3 million

$1.3 million


Net income (loss)

($12.8 million)

($9.6 million)


Earnings per share




Data source: ShockWave Medical.

What happened with ShockWave this quarter

  • The top-line gain was driven by increased adoption of the company's products in both the U.S. and international markets. Revenue was split evenly between the two geographies.
  • ShockWave's products target two main indications: peripheral artery disease (PAD), which is a narrowing of vessels that carry blood from the heart to the extremities, and coronary artery disease (CAD), which is the narrowing of the arteries that supply blood to the heart muscle. PAD products accounted for $4.4 million of total revenue during the quarter; CAD products accounted for $2.7 million of total revenue. It is important to note that CAD products are currently only available for sale in international markets. Management hopes to gain Food and Drug Administration approval to treat CAD indications in the U.S. in the first half of 2021.
  • Gross margin expanded 180 basis points to 58% on the sales leverage.
  • Operating expenses grew 58% to $16.4 million. Management is currently investing heavily in its commercial expansion and clinical pipeline.
  • Net loss was $12.8 million, or $1.37 per share.
  • Its cash balance was $138 million at quarter end. This figure includes the $100 million cash injection from the completion of its IPO and a private placement offering to Abiomed of $10 million.
Man holding a model of a heart

Image source: Getty Images.

What management had to say

CEO Doug Godshall was pleased with the company's first report as a public company: "We are encouraged by the balanced nature of our U.S. and International results this quarter as our global, multi-vessel strategy begins to unfold. Our first-quarter accomplishments begin to demonstrate the unique solution [intravascular lithotripsy] provides for our customers and our team's ability to manage both growth and execution throughout the organization, which we believe will be critical to our success as we move forward."

On the conference call with Wall Street, Godshall also talked up the company's partnership with Abiomed:

The profound and obvious benefit of using ShockWave to facilitate femoral access has really caught the attention of our customers and has emerged as an important sales strategy to accelerate customer acquisition. Abiomed also took note of this last year, which helped motivate their investment in ShockWave and led to the partnership in sales and training that we are in the process of rolling out presently. We have started to witness an increasing number of Shock-Impella cases where ShockWave opens the iliac for Impella delivery, and the keep cases have gone extremely well thus far, which is a great thing for the patients who are able to avoid surgery and receive the Impella they needed.

Check out the latest earnings call transcript for ShockWave.

Looking forward

Management provided investors with an initial look at revenue guidance for the full year. Total sales are expected to land between $33 million and $36 million, which represents growth of 169% to 194% over the prior year. Wall Street was expecting full-year sales of only about $31 million, so ShockWave's stock rocketed higher in response to the news.

Godshall ended his prepared remarks on the investor call by stating that the company is well positioned for rapid growth: 

I'm confident that we have the fundamental pieces in place that will enable us to sustain our momentum. We have an innovative technology with solid clinical results, we're addressing a large unmet need, and we have a driven team that is poised to execute as we grow. We will continue focusing on delivering the positive clinical outcomes we have witnessed to date and building on the organizational momentum that we have seen in our first quarter as a public company.

Brian Feroldi owns shares of Abiomed. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool recommends ShockWave Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ShockWave Medical Stock Quote
ShockWave Medical
$286.87 (2.84%) $7.91
ABIOMED, Inc. Stock Quote
$264.01 (3.47%) $8.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.